Cancer drugs. Smart weapons prove tough to design.
Couzin
Jennifer
J
D026683:Advisory Committees; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004345:Drug Industry; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors / Q000378:metabolism; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D000068877:Imatinib Mesylate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy*; D018579:Patient Selection; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D011799:Quinazolines; D004815:Epidermal Growth Factor; D000068877:Imatinib Mesylate; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib